Gene:
NR3C1
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs10482633 1106+28688A>C, 1184+28688A>C, 142750533T>G, 179+28688A>C, 194+28688A>C, 239+28688A>C, 3913460T>G, 69545A>C, 893+28688A>C, 917+28688A>C, 929+28688A>C
T > G
Intronic
No VIP available No Clinical Annotations available VA
rs852977 1177+2168T>C, 1201+2168T>C, 1213+2168T>C, 132584T>C, 1390+2168T>C, 142687494A>G, 1468+2168T>C, 1471+2168T>C, 3850421A>G, 463+2168T>C, 478+2168T>C, 523+2168T>C
A > G
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  GR
PharmGKB Accession Id: PA181

Details

Cytogenetic Location: chr5 : q31.3 - q31.3
GP mRNA Boundary: chr5 : 142657496 - 142815077
GP Gene Boundary: chr5 : 142654496 - 142825077
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Glucocorticoid Pathway (Peripheral Tissue), Pharmacodynamics
    Genes involved in mediating glucocorticoid effects at the tissue level in the CNS and in the peripheral tissues including heart, lung, vasculatrue and guts.

External Pathways

Links to non-PharmGKB pathways.

  1. carm1 and regulation of the estrogen receptor - (BioCarta via Pathway Interaction Database)
  2. chromatin remodeling by hswi/snf atp-dependent complexes - (BioCarta via Pathway Interaction Database)
  3. corticosteroids and cardioprotection - (BioCarta via Pathway Interaction Database)
  4. FOXA2 and FOXA3 transcription factor networks - (Pathway Interaction Database NCI-Nature Curated)
  5. nfkb activation by nontypeable hemophilus influenzae - (BioCarta via Pathway Interaction Database)
  6. nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells - (BioCarta via Pathway Interaction Database)
  7. Regulation of Androgen receptor activity - (Pathway Interaction Database NCI-Nature Curated)
  8. Regulation of glucocorticoid receptor - (Pathway Interaction Database NCI-Nature Curated)
  9. Regulation of nuclear SMAD2/3 signaling - (Pathway Interaction Database NCI-Nature Curated)
  10. rna polymerase iii transcription - (BioCarta via Pathway Interaction Database)
  11. Signaling events mediated by HDAC Class II - (Pathway Interaction Database NCI-Nature Curated)
  12. the information processing pathway at the ifn beta enhancer - (BioCarta via Pathway Interaction Database)
  13. visceral fat deposits and the metabolic syndrome - (BioCarta via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
antidepressants
No related diseases are available

Publications related to NR3C1: 22

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. Pharmacogenomics. 2012. Narasimhan Sneha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation at GLCCI1 and FCER2: one step closer to personalized asthma treatment. Pharmacogenomics. 2012. Maitland-van der Zee Anke Hilse, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. The pharmacogenomics journal. 2012. Perlis R H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Key pathways are frequently mutated in high risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011. Zhang Jinghui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Quantitative analysis and modeling of glucocorticoid-controlled gene expression. Pharmacogenomics. 2010. Chen Daphne Wei-Chen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in reproductive and perinatal medicine. Pharmacogenomics. 2010. Alfirevic Ana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms in the TATA box and upstream phenobarbital-responsive enhancer module of the UGT1A1 promoter have combined effects on UDP-glucuronosyltransferase 1A1 transcription mediated by constitutive androstane receptor, pregnane X receptor, or glucocorticoid receptor in human liver. Drug metabolism and disposition: the biological fate of chemicals. 2009. Li Ye, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS computational biology. 2009. Xie Li, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic predictors of response to antidepressants in the GENDEP project. The pharmacogenomics journal. 2009. Uher Rudolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (New York, N.Y.). 2008. Mullighan Charles G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Response to prednisone in relation to NR3C1 intron B polymorphisms in childhood nephrotic syndrome. Pediatric nephrology (Berlin, Germany). 2008. Zalewski Grzegorz, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. Molecular pharmacology. 2008. Onica Tania, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007. Kishi Shinji, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Molecular pharmacology. 2006. Duret Cedric, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005. Rocha Jose Claudio C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Human molecular genetics. 2004. Tantisira Kelan G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of a novel glucocorticoid receptor mutation in budesonide-resistant human bronchial epithelial cells. Molecular endocrinology (Baltimore, Md.). 2003. Kunz Susan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tissue glucocorticoid resistance/hypersensitivity syndromes. The Journal of steroid biochemistry and molecular biology. 2003. Kino Tomoshige, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002. Yeoh Eng-Juh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittel-Forschung. 1998. Smith C L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. The Journal of clinical endocrinology and metabolism. 1998. Huizenga N A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. The Journal of steroid biochemistry and molecular biology. 1993. Isogai M, et al. PubMed